DBV Technologies S.A. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DBV Technologies S.A. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.64M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.15M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $15.73M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $4.84M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $5.71M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $11.28M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $14.71M | Mar 17, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($146.95M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($113.92M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $72.71M | Apr 28, 2025 |
| FY2024 | Dec 31, 2022 | $96.27M | Apr 28, 2025 |
| FY2022 | Dec 31, 2021 | ($97.81M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($159.56M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($172.01M) | Mar 17, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($147.06M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($116.59M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($76.43M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($96.63M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($98.61M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($158.84M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($171.02M) | Mar 17, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.68M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $89.34M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $60.22M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $75.54M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $70.34M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $101.61M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $115.10M | Mar 17, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($121.18M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($104.47M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($79.65M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($55.67M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($108.24M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($165.61M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($148.35M) | Mar 17, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $532.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.34M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $677.0K | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $754.0K | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $910.0K | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $2.79M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $5.57M | Mar 17, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.72M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $65.66M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $182.99M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $246.52M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $146.72M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $272.25M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $271.73M | Mar 17, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.95M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $38.27M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $42.80M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $52.06M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $47.45M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $66.75M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $78.54M | Mar 17, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.77M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $27.39M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $140.19M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $194.45M | Apr 11, 2025 |
| FY2023 | Dec 31, 2021 | $99.27M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $205.49M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $193.19M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $138.87M | Mar 17, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($393.13M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($286.38M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($238.86M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($259.58M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($258.53M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($958.54M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($798.99M) | Mar 17, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $194.17M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $32.46M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $141.37M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $209.19M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $77.30M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $196.35M | Mar 9, 2022 |
| FY2021 | Dec 31, 2019 | $193.26M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $140.57M | Mar 17, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $510.0K | Mar 2, 2023 |
| FY2022 | Dec 31, 2020 | $1.27M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $1.46M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $2.84M | Mar 17, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 2, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 2, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 102.85M | Apr 11, 2025 |